GH Research (NASDAQ:GHRS) Trading Up 0.6% – What’s Next?

GH Research PLC (NASDAQ:GHRS)’s share price was up 0.6% during mid-day trading on Friday . The company traded as high as $9.05 and last traded at $8.67. Approximately 20,249 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 79,364 shares. The stock had previously closed at $8.62.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on GHRS shares. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of GH Research in a report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Stock Performance

The company’s 50-day moving average price is $7.80 and its 200 day moving average price is $10.45. The stock has a market capitalization of $448.48 million, a PE ratio of -12.94 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last posted its earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. Analysts expect that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP boosted its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 19.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,966,726 shares of the company’s stock after acquiring an additional 656,163 shares during the period. GH Research accounts for about 16.7% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 3rd largest holding. Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).